

Wednesday, 10 August 2022

ACL FY22 FINANCIAL RESULTS

The following announcements to the market are attached:

- ✓ FY22 Appendix 4E

FY22 full year financial statements and statutory reports, including the FY22 directors' report

FY22 financial results investor presentation

– ENDS –

This announcement was authorised for release to ASX by the Board of ACL. For further information regarding this announcement, please contact:

Company Secretary

Eleanor Padman

Company Secretary

Email: epadman@padmanadvisory.com.au

Phone: +61 (0) 422 002 918

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.

ASX Listing Rule 4.3A

Current reporting period:

Financial year ended 30 June 2022

Previous reporting period:

Financial year ended 30 June 2021

Results for announcement to the market		Percentage change %	30 June 2022 \$'m
Statutory			
Total revenue from ordinary activities	Up	54.0%	995.6m
Profit attributable to members of Australian Clinical Laboratories Limited	Up	195.2%	178.2m
Pro forma*			
Total revenue from ordinary activities	Up	47.6%	995.6m
Profit attributable to members of Australian Clinical Laboratories Limited	Up	100.9%	178.2m

* In FY21, in line with the prospectus dated 28 April 2021, pro forma financials were reported to normalise results which removed initial public offer (IPO) transaction costs, SunDoctors acquisition and other significant one off costs.

Earnings per share		Percentage change %	30 June 2022 Cents per share
Statutory			
Basic earnings per share	Up	123.1%	88.55c
Diluted earnings per share	Up	122.9%	88.46c
Pro forma			
Basic earnings per share	Up	51.8%	88.55c
Diluted earnings per share	Up	51.6%	88.46c

Dividends		Amount per security Cents per share	Franked amount per security Cents per share
FY2022			
Final dividend		41.00c	41.00c
Interim dividend		12.00c	12.00c
FY2021			
Final dividend		Nil	Nil
Pre IPO dividend		14.25c	14.25c

Record date for determining entitlements to the final dividend

24 August 2022

Payment date

15 September 2022

There is a dividend reinvestment plan in operation. The last day for the receipt of an election notice for participation is Thursday 25 August 2022.

Commentary on results for the period

For an explanation of the results refer to the ASX and media release and Annual Financial Report.

Net tangible assets per ordinary security	30 June 2022	30 June 2021
Net tangible assets per ordinary security	\$0.33	(\$0.15)
Net asset backing per ordinary security	\$1.15	\$0.41

Table above includes right-of-use assets and liabilities recognised in accordance with AASB 16 Leases.

This report is based on the Annual Financial Report which has been audited. Additional Appendix 4E disclosure requirements can be found in the Annual Financial Report attached, which contains the Directors' Report, the audited Remuneration Report, the Directors' Declaration and the consolidated financial statements.